Combined effect of sodium selenite and docetaxel on PC3 metastatic prostate cancer cell line

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Docetaxel is a key chemotherapy for prostate cancer, but resistance is a significant challenge.
• Sodium selenite presents a novel therapeutic strategy with anticancer properties.
• Combination therapies targeting multiple cellular pathways are crucial for overcoming drug resistance.

Purpose of the Study:

• To investigate the synergistic effects of combining docetaxel and sodium selenite on the PC3 prostate cancer cell line.
• To evaluate the impact of this combination on cell growth, cell cycle, viability, and apoptotic pathways.

Main Methods:

• PC3 prostate cancer cells were treated with docetaxel, sodium selenite, or their combination.
• Assays included cell growth, cell cycle progression, viability, mitochondrial membrane potential, cytochrome C, Bax/Bcl2 ratio, caspase-3 expression, and reactive oxygen species production.

Main Results:

• The combination of sodium selenite and docetaxel demonstrated a synergistic effect, inhibiting cell growth by 67%, compared to 22% for docetaxel and 24% for sodium selenite alone.
• The combination significantly induced cell death, primarily through late apoptosis, linked to mitochondrial membrane potential depletion.
• While sodium selenite alone increased proapoptotic factors (cytochrome C, Bax/Bcl2 ratio, caspase-3), the combination did not show this effect.

Conclusions:

• Docetaxel and sodium selenite combination exhibits synergistic anticancer activity against prostate cancer cells.
• This combination induces cell death via apoptosis and may overcome docetaxel resistance.
• Further research into this combination as a prostate cancer therapeutic approach is warranted.